Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain.

ABSTRACT: Olanzapine is one of the most effective medicines available for stabilizing schizophrenia spectrum disorders. However, it has been reported to show the greatest propensity for inducing body weight gain and producing metabolic side effects, which cause a great burden in patients with psychiatric disorders. Since the gut microbiota has a profound impact on the initiation and development of metabolic diseases, we conducted a longitudinal study to explore its role in olanzapine-induced obesity and metabolic abnormalities. Female Sprague-Dawley rats were treated with different doses of olanzapine, and metabolic and inflammatory markers were measured. Olanzapine significantly induced body weight gain (up to a 2.1-fold change), which was accompanied by hepatic inflammation and increased plasma tr

SUBMITTER: Qian L 

PROVIDER: S-EPMC10433857 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature